International Association for the Study of Pain

Why pain is so hard to measure – and how our study of brainwaves could help

Retrieved on: 
Friday, August 4, 2023

The experience of pain remains impenetrable to scientists because it is so variable.

Key Points: 
  • The experience of pain remains impenetrable to scientists because it is so variable.
  • So researchers and clinicians still rely on subjective ratings, such as asking patients to rate their pain on a scale of zero to ten.
  • Pain is often different in quality (dull, sharp, shocking, throbbing) and it may be hard to remember properly.

The long search for a pain gauge

    • In the early 1990s, neuroimaging techniques such as PET scans and fMRIs became a popular way to study pain.
    • Both your brain response and your conscious perception of pain are influenced by how much attention you pay to it.
    • There is growing evidence that brain response to pain doesn’t always have a meaningful relationship to the level of pain a person is experiencing – heightened brain activity doesn’t always mean heightened pain.

Brain oscillations

    • In the 2000s, experimental work showed that gamma oscillations increased in amplitude following both brief and prolonged thermal painful stimuli in healthy volunteers.
    • Gamma oscillations may control the connectivity between different brain regions.
    • Patient research and recording of electrical activity within the brain seemed to support the idea that gamma oscillations could reflect pain perception better than any other brain response to pain.

What our results mean

    • Our findings suggest we must rethink our interpretation of the relationship between pain and gamma oscillations, but that it’s still too early for general rules.
    • Some people will feel pain and have no gamma response, while others will show a large response.
    • For example, people with chronic pain conditions may have changes in their brain structure and response to pain.

Aspen Medical Products Expands Pain Management Solutions with the Launch of the Horizon PRO Line

Retrieved on: 
Tuesday, June 13, 2023

IRVINE, Calif., June 13, 2023 /PRNewswire/ -- Aspen Medical Products (Aspen), the industry leader in solutions for mobility and pain management, has launched the Horizon PRO line of lower spine braces designed to alleviate symptoms related to lower back pain caused by muscle fatigue and spasms.

Key Points: 
  • IRVINE, Calif., June 13, 2023 /PRNewswire/ -- Aspen Medical Products (Aspen), the industry leader in solutions for mobility and pain management, has launched the Horizon PRO line of lower spine braces designed to alleviate symptoms related to lower back pain caused by muscle fatigue and spasms.
  • Conservative pain management solutions are needed for a growing elderly population and to limit dependence on prescription pain relief.
  • Preceded by the Horizon classic line, the Horizon PRO line provides an upgraded approach to pain management while utilizing Aspen's clinically trusted tri-band technology.
  • "With the new Horizon PRO line, we have added significant improvements to our proven Horizon technology, enabling us to deliver superior pain management and enhanced mobility."

Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain

Retrieved on: 
Tuesday, May 30, 2023

Algiax Pharmaceuticals , today provided an update on its ongoing Phase 2a study ( NCT04429919 ) with lead candidate AP-325 in patients with chronic neuropathic pain.

Key Points: 
  • Algiax Pharmaceuticals , today provided an update on its ongoing Phase 2a study ( NCT04429919 ) with lead candidate AP-325 in patients with chronic neuropathic pain.
  • The study is continuing as planned with topline efficacy readouts and a more in-depth safety analysis expected at the conclusion in 2024.
  • Neuropathic pain is a chronic condition that is oftentimes associated with an imbalance in excitatory and inhibitory neuronal signals.
  • In its preclinical evaluation, Aligax’s lead candidate demonstrated dose-dependent, long-lasting efficacy on mechanical and thermal pain reception in models of central neuropathic pain, peripheral neuropathic pain, and diabetic neuropathy.

Research Describes Novel Laboratory Automation Platform for Preclinical Detection and Quantification of Behavior

Retrieved on: 
Wednesday, March 8, 2023

BOSTON and DALLAS, March 8, 2023 /PRNewswire/ -- Researchers at Boston Children's Hospital and Harvard Medical School's Department of Neurobiology have developed a new approach to measure dynamic changes in behavior in an unbiased, observer-independent manner, according to a new study published in and featured on the cover of PAIN, the journal of the International Association for the Study of Pain (IASP). The investigators noted that this technology platform has the ability to characterize a broad range of physiological and pathological phenomena and can be applied to objectively and automatically characterize behaviors including such tactile hyperalgesia, sedation, and other neurological readouts.

Key Points: 
  • Results suggest new technology enables improved, high-volume characterization and quantification of in vivo behavior.
  • Principal Investigator, Clifford Woolf, Mb, BCh, PhD, Professor of Neurobiology at Harvard Medical School and Director of the F.M.
  • Kirby Neurobiology Center at Boston Children's Hospital
    This peer-reviewed study demonstrated the efficacy of a novel automated technology platform in recording freely behaving mice over time for continuous data acquisition.
  • In addition, researchers utilized a proprietary machine learning software for automatic extraction and quantification of behavior characters, allowing for objective, sensitive, and high-throughput measurement of the behavioral state of rodents.

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Compounding Pharmacies Global Market Report 2022: Featuring Avella Specialty Pharmacy, Fagron, PharMEDium, B Braun Melsungen & More - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022

The "Compounding Pharmacies Market, by Product Type, by Therapeutic Area, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Compounding Pharmacies Market, by Product Type, by Therapeutic Area, by Application, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Compounded medications are prepared by compounding pharmacies to meet the needs of unique patients whose conditions cannot be treated by commercially accessible medications.
  • The process of combining, blending, or changing substances to make a treatment specific to the requirements of a particular patient is known as drug compounding.
  • Combining two or more medications is referred to as compounding.

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th

Retrieved on: 
Thursday, October 20, 2022

Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.

Key Points: 
  • Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.
  • In addition, Tremeaus Founder and CEO Bradford C. Sippy will discuss the companys development pipeline, including Phase III-ready TRM-201 (rofecoxib).
  • Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine.
  • Tremeaus lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic with a well-established benefit-risk profile.

DarioHealth Publishes New Clinical Research Linking the Use of its Biofeedback Device to Reduced Back Pain

Retrieved on: 
Thursday, September 22, 2022

 NEW YORK, Sept. 22, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use of Dario's biofeedback device to help users improve their posture and reduced back pain at the International Association of the Study of Pain (IASP) 2022 World Congress on Pain, being held in person in Toronto, Ontario from September 19th – 23rd and virtually.

Key Points: 
  • The new research examined the connection between users of Dario's posture trainer, posture awareness and the impact on levels of pain.
  • Over the course of time, this trains users, helping them to develop awareness and adoption of proper posture.
  • "Dario's posture trainer is proven to help users reduce back pain, and with this new research we now better understand the connection between device, training and results.
  • "Dario's approach to research involves both testing the efficacy of solutions as well as seeking to understand the mediators of clinical improvement.

Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain

Retrieved on: 
Thursday, September 15, 2022

We are excited to be presenting preclinical profiling details for our novel AT2R inhibitor, CFTX-1554, alongside research into its mechanism of action at the IASP congress, said Dr. Christel Menet, CSO of Confo Therapeutics.

Key Points: 
  • We are excited to be presenting preclinical profiling details for our novel AT2R inhibitor, CFTX-1554, alongside research into its mechanism of action at the IASP congress, said Dr. Christel Menet, CSO of Confo Therapeutics.
  • The data from these in vivo and ex vivo studies support the potential efficacy of CFTX-1554 as a novel analgesic and suggest new hypotheses that inform its mechanism of action.
  • With our Phase 1 study for CFTX-1554 ongoing, we look forward to substantiating these results in the clinic.
  • The compound is a novel inhibitor of angiotensin II type 2 receptor (AT2R), a clinically precedented target for the treatment of neuropathic pain.